Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Trial of Exl-111 in Healthy Participants
NCT07356713Phase 1Recruiting
- Sponsor
- Excellergy Therapeutics
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of EXL-111 in allergic disease (4 arms), sponsored by Excellergy Therapeutics. Primary endpoint: Incidence and severity of treatment-emergent adverse events and serious adverse events at Day 196. Started Jan 2026; status: recruiting.
02
Drugs
EXL-111
03
Conditions
allergic disease
Beyond the preview
Go deeper on NCT07356713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07356713.